Mysimba: Medical Information, Uses and UK Safety Guidance
If you are researching Mysimba, this guide from Alluvi Healthcare explains what the medicine contains, how it works, its approved medical use, potential side effects and important UK prescription considerations.
What Is Mysimba?
Mysimba is a prescription-only medicine used as part of a weight-management programme for certain adults who meet specific clinical criteria. It contains two active ingredients: naltrexone hydrochloride and bupropion hydrochloride.
These ingredients act on pathways in the brain involved in appetite regulation, food intake and energy expenditure. Mysimba is intended to be used alongside a reduced-calorie diet and increased physical activity, rather than as a replacement for healthy lifestyle measures.
How Does Mysimba Work?
Mysimba combines two active substances that affect different pathways involved in appetite and food-related behaviour:
- Naltrexone: Acts on opioid receptors and influences pathways associated with reward and food-related behaviour.
- Bupropion: Influences noradrenaline and dopamine signalling, which are involved in appetite regulation and energy balance.
The combined action is intended to help eligible patients manage food intake as part of a broader weight-management programme. Individual responses vary, and treatment requires medical supervision.
Who May Be Eligible for Mysimba?
According to the authorised product information, Mysimba is indicated for adults aged 18 and over who meet specified body mass index (BMI) criteria:
- An initial BMI of 30 kg/m² or above; or
- An initial BMI of at least 27 kg/m² but below 30 kg/m², alongside one or more weight-related conditions such as type 2 diabetes, dyslipidaemia or controlled hypertension.
Eligibility must be assessed by an appropriately qualified healthcare professional. BMI alone does not establish that this medicine is suitable for an individual.
Mysimba UK: Prescription and Regulatory Information
Mysimba is classified as a prescription-only medicine in the UK. It should only be prescribed and supplied through appropriate lawful healthcare and pharmacy arrangements.
The medicine is available as prolonged-release tablets containing 8 mg naltrexone hydrochloride and 90 mg bupropion hydrochloride per tablet. The official product information should be consulted for the full composition, warnings and prescribing requirements.
Prescription treatment requires an assessment of medical history, current medicines, blood pressure and relevant risk factors. A healthcare professional should also review whether continued treatment remains appropriate.
Possible Side Effects of Mysimba
Like other prescription medicines, Mysimba can cause side effects. Commonly reported effects include:
- Nausea and vomiting
- Constipation
- Headaches
- Dizziness
- Dry mouth
- Difficulty sleeping
- Anxiety or restlessness
- Palpitations or increased blood pressure
More serious reactions can occur, including seizures, significant blood-pressure changes and psychiatric or allergic reactions. The full patient information leaflet explains the recognised risks and when medical attention is required.
Important Precautions and Contraindications
Mysimba is not suitable for everyone. The official product information identifies circumstances in which it must not be used, including:
- Uncontrolled high blood pressure
- A current seizure disorder or a history of seizures
- Current or previous bulimia or anorexia nervosa
- A history of bipolar disorder
- Severe liver impairment or end-stage kidney failure
- Current dependence on chronic opioids or certain opioid treatments
- Concurrent use of medicines containing naltrexone or bupropion
- Use of certain monoamine oxidase inhibitor medicines
This is not a complete list. Other conditions and medicines may also affect suitability. Patients should disclose their full medical history and medication list to their prescriber.
Monitoring During Treatment
Medical monitoring is important during treatment with Mysimba. Healthcare professionals may need to review blood pressure, treatment response, tolerability and other relevant health factors.
The authorised product information recommends reassessing treatment after 16 weeks. Treatment should be discontinued if the patient has not lost at least 5% of their initial body weight by that point. The need for continued treatment should also be reviewed regularly.
Patients should not change or stop prescribed treatment without discussing their circumstances with their healthcare professional, unless they require urgent medical attention.
Weight Management Information
Mysimba is intended to be part of a wider weight-management approach that includes dietary changes and physical activity. Treatment decisions should take account of individual health needs, potential benefits and possible risks.
For general category information, see Alluvi Healthcare Weight Loss. The presence of a medicine in a category does not establish its suitability for an individual or replace the need for a valid prescription and appropriate professional assessment.
Frequently Asked Questions About Mysimba
What does Mysimba contain?
Mysimba contains two active ingredients: naltrexone hydrochloride and bupropion hydrochloride. The combination acts on brain pathways involved in appetite regulation and food intake.
Is Mysimba prescription-only in the UK?
Yes. Mysimba is a prescription-only medicine in the UK and requires appropriate assessment and prescribing by a qualified healthcare professional.
What is Mysimba used for?
Mysimba is authorised for weight management in certain adults who meet specified BMI criteria. It is used alongside a reduced-calorie diet and increased physical activity.
What are the common side effects of Mysimba?
Common side effects include nausea, vomiting, constipation, headache, dizziness, dry mouth and difficulty sleeping. Other important risks are explained in the official patient information leaflet.
Can everyone use Mysimba?
No. Certain medical conditions, medicines and risk factors make Mysimba unsuitable. A healthcare professional must assess eligibility and safety before prescribing it.
How is treatment with Mysimba monitored?
Monitoring may include reviewing blood pressure, side effects, treatment response and ongoing suitability. The official product information recommends reassessing treatment after 16 weeks.
Official Medical Information and References
- Mysimba Summary of Product Characteristics
- Mysimba Patient Information Leaflet
- NICE guidance on naltrexone-bupropion
- MHRA safety information about Mysimba and driving
About Alluvi Healthcare
Alluvi Healthcare provides healthcare information to help visitors understand medicines, treatment considerations and responsible healthcare decisions. Learn more on our About Alluvi Healthcare page or contact the team through our Contact page.
Medical disclaimer: This page is for general educational purposes only. It is not medical advice, a diagnosis or a recommendation to use Mysimba. Mysimba is a prescription-only medicine. Always consult an appropriately qualified healthcare professional about its suitability, risks and treatment.






